Peptide-based Metabolic Disorders Therapeutics Market

Peptide-based Metabolic Disorders Therapeutics Market is segmented by Product (GLP-1 Receptor Agonists, Dual GLP-1/GIP Agonists, Amylin & Other Peptide Analogues, Insulin & Insulin Analogues), Application (Obesity Management, Type 2 Diabetes, Cardiometabolic Disorders, Endocrine Disorders), End Use (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Specialty Weight Loss Clinics, Research & Academic Institutes), and Region, with forecasts covering the period from 2026 to 2036.